Tyler Eck

Tyler Eck

Auto-generated profile, based on publicly available information

Tyler Eck

Affiliations Montclair State University and the Sokol Institute of Pharmaceutical Life Sciences, Montclair, New Jersey, United States of America, Department of Microbiology, Biochemistry and Molecular Genetics. New Jersey Medical School, Newark, New Jersey, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in ChemBioChem
Verified
Journal Article
Open access
PDF file
TETyler Eck
Tyler Eck
MSMariana Laureano de Souza
Mariana Laureano de Souza
MDMelvin Delvillar
Melvin Delvillar
KAKutub Ashraf
Kutub Ashraf
RBRammohan R. Yadav Bheemanaboina
Rammohan R. Yadav Bheemanaboina
NGNina Goodey
Nina Goodey
Plasmodium falciparum cGMP‐dependent protein kinase (PfPKG) is an enticing antimalarial drug target. Novel chemotypes are needed because existing inhibitors have safety issues that may prevent further development. This work demonstrates isoxazole‐based compounds are potent ATP competitive inhibitors of PfPKG and discloses a new analogue in this series. Isoxazoles 3 and 5 had Ki values that are comparable to a known standard, 4‐[2‐(4‐fluorophenyl)‐5‐(1‐methylpiperidine‐4‐yl)‐1H pyrrol‐3‐yl] pyridine. They also exhibited excellent selectivity for PfPKG over the human orthologue and the gatekeeper mutant T618Q PfPKG, which mimics the less accessible binding site of the human orthologue. The human orthologue's larger binding site volume is predicted to explain the selectivity of the inhibitors for the P. falciparum enzyme.

16 March 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TKTamara Kreiss
Tamara Kreiss
TETyler Eck
Tyler Eck
BHBrittany Hart
Brittany Hart
STSreedhar Tummalapalli
Sreedhar Tummalapalli
DRDavid Rotella
David Rotella
John SiekierkaJohn Siekierka
John Siekierka
Filariasis, caused by a family of parasitic nematodes, affects millions of individuals throughout the tropics and is a major cause of acute and chronic morbidity. Current drugs are largely used in mass drug administration programs aimed at controlling the spread of disease by killing microfilariae, larval forms of the parasite responsible for transmission from humans to humans through insect vectors with limited efficacy against adult parasites. Although these drugs are effective, in some cases there are toxic liabilities. In case of loiasis which is caused by the parasitic eyeworm Loa loa, mass drug administration is contraindicative due to severe side effects of microfilariae killing, which can be life threatening. Our screening program and medicinal chemistry efforts have led to the identification of a novel series of compounds with potent killing activity against adult filarial parasites and minimal activity against microfilariae. A structural comparison search of our compounds demonstrated a close structural similarity to a recently described histone demethylase inhibitor, GSKJ1/4 which also exhibits selective adult parasite killing. We demonstrated a modification of histone methylation in Brugia malayi parasites treated with our compounds which might indicate that the mode of drug action is at the level of histone methylation. Our results indicate that targeting B. malayi and other filarial parasite demethylases may offer a novel approach for the development of a new class of macrofilaricidal therapeutics.

1 October 2020 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
TETyler Eck
Tyler Eck
SPSeema Patel
Seema Patel
TCThomas Candela
Thomas Candela
KHKatherine Leon H
Katherine Leon H
MLMichael Little
Michael Little
NGNina Goodey
Nina Goodey